Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

107 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
HIV type 1 DNA development during long-term supervised therapy interruption.
Eriksson LE, Falk KI, Bratt GA, Leandersson AC, Wahren B, Leitner T. Eriksson LE, et al. AIDS Res Hum Retroviruses. 2003 Apr;19(4):259-65. doi: 10.1089/088922203764969456. AIDS Res Hum Retroviruses. 2003. PMID: 12804001 Clinical Trial.
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839 Clinical Trial.
The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life.
Eriksson LE, Bratt GA, Sandström E, Nordström G. Eriksson LE, et al. Health Qual Life Outcomes. 2005 May 4;3:32. doi: 10.1186/1477-7525-3-32. Health Qual Life Outcomes. 2005. PMID: 15871738 Free PMC article.
Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B. Rollman E, et al. Vaccine. 2007 Mar 1;25(11):2145-54. doi: 10.1016/j.vaccine.2006.10.057. Epub 2006 Nov 13. Vaccine. 2007. PMID: 17254672
Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E. Bråve A, et al. Vaccine. 2007 Sep 28;25(39-40):6882-90. doi: 10.1016/j.vaccine.2007.07.012. Epub 2007 Jul 27. Vaccine. 2007. PMID: 17707956
Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
Eriksson LE, Nilsson Schönnesson L, Bratt GA. Eriksson LE, et al. Biol Res Nurs. 2011 Jan;13(1):89-96. doi: 10.1177/1099800409350677. Epub 2009 Nov 25. Biol Res Nurs. 2011. PMID: 19942593
Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC).
Palma P, Romiti ML, Montesano C, Santilli V, Mora N, Aquilani A, Dispinseri S, Tchidjou HK, Montano M, Eriksson LE, Baldassari S, Bernardi S, Scarlatti G, Wahren B, Rossi P. Palma P, et al. PLoS One. 2013 Nov 28;8(11):e79957. doi: 10.1371/journal.pone.0079957. eCollection 2013. PLoS One. 2013. PMID: 24312194 Free PMC article. Clinical Trial.
Immunotherapy with an HIV-DNA Vaccine in Children and Adults.
Palma P, Gudmundsdotter L, Finocchi A, Eriksson LE, Mora N, Santilli V, Aquilani A, Manno EC, Zangari P, Romiti ML, Montesano C, Grifoni A, Brave A, Ljungberg K, Blomberg P, Bernardi S, Sandström E, Hejdeman B, Rossi P, Wahren B. Palma P, et al. Vaccines (Basel). 2014 Jul 17;2(3):563-80. doi: 10.3390/vaccines2030563. Vaccines (Basel). 2014. PMID: 26344746 Free PMC article.
Development and psychometric testing of a barriers to HIV testing scale among individuals with HIV infection in Sweden; The Barriers to HIV testing scale-Karolinska version.
Wiklander M, Brännström J, Svedhem V, Eriksson LE. Wiklander M, et al. Health Qual Life Outcomes. 2015 Nov 19;13:185. doi: 10.1186/s12955-015-0381-7. Health Qual Life Outcomes. 2015. PMID: 26584977 Free PMC article.
107 results
Jump to page
Feedback